In the past year, the FDA has approved several oncology drugs for solid tumors, as highlighted by Dr. Kirollos S. Hanna from M Health Fairview during JADPRO Live Virtual 2020. Notable approvals include enfortumab vedotin for advanced bladder cancer, fam-trastuzumab deruxtecan for HER2-positive breast cancer, and tucatinib for HER2-positive metastatic breast cancer with notable efficacy in patients with brain metastases. Safety profiles were examined, revealing common adverse effects; some treatments also posed significant risks of serious toxicities. Dr. Hanna also covered expanded indications for immunotherapy drugs.
1. Several oncology drugs were FDA approved in the last year. 2. Enfortumab vedotin shows a 44% response rate in advanced bladder cancer. 3. Fam-trastuzumab deruxtecan had a 61% response rate in HER2+ breast cancer. 4. Tucatinib is effective for HER2+ breast cancer with brain metastases. 5. Safety assessments revealed significant adverse effects for some treatments. 6. Immunotherapy approvals expanded, including pembrolizumab and ipilimumab combinations.
Listen Tab content
